Pulse Biosciences, Inc.

NASDAQ:PLSE

Medical - Instruments & Supplies

Healthcare
$45.83 +3.83%

+$0.97 today

Market cap
$3.37B
Beta
1.66
P/E (TTM)
-24.0
EPS (TTM)
-$1.10
52W Low $12.56High $28.53

Volume 0.33M

Average 0.31M

PLSE Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Pulse Biosciences, Inc.NASDAQ: PLSE

Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026

Other income / expenses declines year over year

Q2 FY2026 other income / expenses of $615K fell 44.4% year over year, behind the -29.0% change in trailing-twelve-month other income / expenses. Sequentially, it rose 8.1% from the prior quarter.

Context

  • Other income / expenses amounted to 1188.0% of revenue in FY2025.
  • Other income / expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -44.4% toward the trailing-twelve-month pace of -29.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$615K+8.1% QoQ
Last fiscal yearDec 2025
$4.16M+55.6% YoY
LTMJun 2026
$2.99M-29.0% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-44.4%——
1 year+55.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
4.16M USD
Year-over-year change
+55.6%

Other Income / Expenses vs competitors

How PLSE compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -29.0% is the 6th highest of 11, against a peer median of -47.3%.
  • Other income / expenses amounts to 252.0% of revenue for PLSE, versus a peer median of 6.0%.
PLSE Competitors
Other Income / Expenses for PLSE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$187.94M USD+1139.2%+133.2%9870.5%
BBNXBeta Bionics, Inc.LTM Mar 2026$10.87M USD+165.8%—9.9%
NVCRNovoCure LimitedLTM Mar 2026$8.14M USD-78.0%+31.7%1.2%
PLSEPulse Biosciences, Inc.LTM Jun 2026$2.99M USD-29.0%—252.0%
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026-$75K USD+98.8%—0.1%
LFMDLifeMD, Inc.LTM Mar 2026-$2M USD+14.1%—0.9%
IMTXImmatics N.V.LTM Mar 2026-€2.64M EUR-106.2%—7.1%
STAASTAAR Surgical CompanyLTM Apr 2026-$14.55M USD-327.2%—5.0%
NKTRNektar TherapeuticsLTM Jun 2026-$25.52M USD-16.6%—46.8%
OPKOPKO Health, Inc.LTM Mar 2026-$26.13M USD-117.8%—4.5%
ATAIAtai Beckley Inc.LTM Jun 2026-$521.72M USD-2303.3%—11663.8%
Peer median (excluding PLSE) —-47.3%+82.5%6.0%

Competitors are the stored peer set for PLSE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.42M700K00350K
Cost of Revenue1.97M11.94M1.21M01.61M
Gross Profit(550K)(11.24M)(1.21M)0(1.26M)
Gross Margin-38.8%-1606.3%——-360.0%
Research & Development28.64M20.84M27.8M32.34M44.72M
Selling, General & Admin33.82M25.97M15.78M23.92M32.03M
Operating Expenses62.46M46.81M42.37M56.26M75.68M
Depreciation & Amortization1.15M1.36M1.21M1.18M1.07M
EBITDA(62.51M)(57.15M)(39.9M)(52.41M)(71.71M)
EBITDA Margin-4408.6%-8164.3%——-20488.6%
Operating Income(63.01M)(58.06M)(43.57M)(56.26M)(76.94M)
Operating Margin-4443.9%-8293.9%——-21982.6%
Interest Income002.46M2.67M4.21M
Interest Expense646K448K1.1M00
Other Income / Expenses(646K)(448K)1.36M2.67M4.16M
Income Before Tax(63.66M)(58.51M)(42.21M)(53.59M)(72.78M)
Pre-Tax Margin-4489.4%-8357.9%——-20794.6%
Income Tax Expense00000
Net Income(63.66M)(58.51M)(42.21M)(53.59M)(72.78M)
Net Margin-4489.4%-8357.9%——-20794.6%
EPS (Basic)(2.28)(1.72)(0.88)(0.92)(1.08)
EPS (Diluted)(2.28)(1.72)(0.88)(0.92)(1.08)
Weighted Avg Shares27.96M33.94M48.04M58.4M67.4M
Weighted Avg Shares (Diluted)27.96M33.94M48.04M58.4M67.4M

Pulse Biosciences, Inc.

NASDAQ:PLSE

Intrinsic Alpha fair value

Locked

Current Price

$45.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.